Further, we found that sevoflurane‐induced cognitive impairment was linked with the inhibition of the AKT/mTOR‐mediated autophagy pathway, suggesting that interventions for this pathway might be a potential target for developing therapies to combat sevoflurane‐induced cognitive decline associated with tau pathology. The gene discussed is MAPT; the disease is Cognitive impairment.